Aplastic Anemia Clinical Trials

Not all trials are listed on www.ClinicalTrials.gov. The investigators may have chosen not to register the trial, or the study may not be eligible to be listed on ClinicalTrials.gov. If the study has not, for example, been approved by a human subject review board, it cannot be posted. Some trials are not listed because the investigators are not planning to publish the research findings, so you can ask the study coordinator why the study has not been included on ClinicalTrials.gov before you give your consent to participate.

The information on the studies linked below is provided strictly as a resource, not as an endorsement of any given treatment, doctor, or medical center.

Remember, before you sign a consent form, Clinical Trials Explained can help you understand the potential risks and benefits of a clinical trial. You can also contact the AA&MDSIF staff to discuss any questions you have at clinicaltrials@aamds.org or by calling the office at 301.279.7202 or 800.747.2820.

^{Last Modified: February 2009}

New York � Presbyterian Hospital

fludarabine, cyclophosphamide, and thymoglobulin protocol

Protocol CHNY 01-509 | New York, New York

This is a phase II trial using fludarabine, cyclophosphamide, and Thymoglobulin (anti-thymocyte globulin) to evaluate the efficacy of reduced-intensity allogeneic stem cell transplant to treat aplastic anemia. Eligible patients must have 1) severe aplastic anemia; 2) age less than 56 years; 3) adequate organ function; 4) matched family donor (6/6 or 5/6), unrelated donor(6/6 or 5/6), related or unrelated cord blood. Contact James Garvin, MD at 212.305.5808 or jhg1@columbia.edu.

For patients with: AA

Updated: November 01, 2005

<< Return to List